XASKA Pharmaceutical Co., Ltd.

November 18, 2020

Financial Results of the Second Quarter, FY2020



Stock Code :4514



FORWARD LOOKING STATEMENT

- The forward-looking statements contained in this presentation are based the Company's assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties.
- Accordingly, there is a possibility that actual results and development programmes may differ largely from these forecasts, due to a variety of factors.
- This report contains information on Pharmaceuticals Products (including those under development), but the content of this report is not intended for medical promotion or medical advice.

XASKA Pharmaceutical Co., Ltd.

The First Half of FY2020* Consolidated Financial Summary

ASKA Pharmaceutical Co., Ltd. Atsushi Maruo Executive Director, Representative Director

*Refers to April 1st 2020 to March 31st 2021



Consolidated Statements of Income

Millions of yen	FY2019 Apr-Sep	FY2020 Apr-Sep	Actual +/-	Growth +/-	
Net sales	26,582	27,403	+ 820	+ 3.1%	
Cost of sales	14,492	14,563	+ 70	+ 0.5%	
Gross profit	12,089	12,840	+ 750	+ 6.2%	
Selling, general and administrative expenses	11,343	10,894	- 449	- 4.0%	
Operating profit	746	1,946	+ 1,199	+ 160.7%	
Ordinary profit	869	1,952	+ 1,082	+ 124.5%	
Profit attributable to owners of parent	577	1,552	+ 975	+ 168.9%	
* Put a current exchange rate and the ref (1 US dollar = 103 83 ven, as of Nov 18 th 2020)					

* Put a current exchange rate and the ref (1 US dollar = 103.83 yen, as of Nov 18th 2020)

(1 Euro = 123.06 yen, as of Nov 18th 2020)



Net Sales by Business (Consolidated)

Millions of yen	FY2019 Apr-Sep	FY2020 Apr-Sep	Breakdown	Actual +/-	Growth +/-
Ethical drugs	24,177	25,128	91.7%	+ 951	+ 3.9%
Animal Health	2,319	2,232	8.1%	- 86	- 3.7%
Others	86	42	0.2%	- 44	- 51.0%
Total	26,582	27,403	100.0%	+ 820	+ 3.1%



Sales of Main Products


							Millions of yen
Area Products	FY2019 Apr-Sep	FY2020 Apr-Sep		FY2020			
			Actual	Actual	YOY (%)	Forecast	YOY (%)
	*1 *2	CANDESARTAN	6,878	6,117	88.9%	11,486	86.9%
Inte		THYRADIN	3,433	3,579	104.3%	7,169	104.0%
rnal I		RIFXIMA	1,845	2,176	117.9%	4,829	127.7%
Internal Medicine		MERCAZOLE	700	698	99.7%	1,383	100.2%
cine	*1	AMLODIPINE	790	632	80.0%	1,184	82.4%
		LIPIDIL	777	590	75.9%	1,187	94.5%
		RELUMINA (2019.3~)	865	2,519	291.1%	5,921	226.4%
Obst Gyr	*1	FREWELL	1,012	1,355	133.9%	2,469	109.8%
Obstetrics and Gynecology	*4	Magsent (2020.2~)	—	466	_	878	1583.7%
s and ogy		ANGE	538	453	84.1%	958	94.9%
		LUTEUM	246	238	96.9%	519	101.0%
Urology	*1 *3	LEUPRORELIN	2,472	2,274	92.0%	3,639	75.9%
ogy	*1	BICALUTAMIDE	692	515	74.5%	1,060	84.3%

* 1 Generic Drugs * 3 1.88mg formulation is for gynecological indications only, but combined with 3.75mg formulation

* 2 Including combination drugs * 4 Total value of magnesium sulfate preparation




Analysis of Increase and Decrease in Operating Profit (YOY)



- Gross profit increased due to growth in "RELUMINA" after the lifting of length of prescription restrictions, steady increase in main products such as "RIFXIMA", and recording of a lump-sum milestone payment related to the Agreement with Kyorin Pharmaceutical.
- Reduction in expenses due to reduction of direct sales activities due to the spread of the novel coronavirus



Consolidated Balance Sheet





FY2020 Forecast (Consolidated)


Millions of yen	FY2019 Results	FY2020 Forecast	YOY Actual +/-	YOY % +/-
Net sales	52,542	53,000	+ 458	+ 0.9%
Operating profit	1,507	2,000	+ 493	+ 32.7%
Ordinary profit	1,715	1,900	+ 185	+ 10.8%
Profit attributable to owners of parent	649	1,500	+ 851	+ 131.1%

Factors

- Sales are expected to increase due to growth in "RELUMINA", contributions from "RIFXIMA" and "Magsent", as well as the recording of a lump-sum milestone payment.
- In terms of profits, operating income, ordinary income, and net income are all expected to increase respectively due to an increase in sales.



Reference



XASKA Pharmaceutical Co., Ltd.

Overview of the First Half of FY2020 Interim Annual Report

ASKA Pharmaceutical Co., Ltd. Takashi Yamaguchi President, Representative Director



Founding 100th Year



<section-header>

Advertised in the Nikkei (June 16, 2020)

ASKA reached its 100th anniversary on June 16, 2020. Since our founding in 1920, the Company has consistently focused on drug discovery. The Company has continued to create and provide pharmaceuticals of value to patients. The past 100 years will be linked to the future. Based on our corporate philosophy of "Contribute toward the improvement of people's health and progress in medicine through the development of innovative products", ASKA Pharmaceutical will continue to be a firm that contributes to people's lives.

Advance further with all the alliances

ANNIVER



Today's Content

Overview of the First Half of FY2020 Initiatives for Major Themes in FY2020 Contribution to Women's Health Care Initiatives in Internal Medicine Research and Development Global Expansion



Overview of the First Half of FY2020



The Impact and Response to the Novel Coronavirus

From the viewpoint of preventing the spread of the novel coronavirus (COVID-19), the Company has taken numerous measures such as: the promotion of working from home, flexible commuting, self-restriction of business activities and travel, development of a Web friendly environment, and the correct utilization of electronic signatures.

In the second quarter of the fiscal year under review, the impact to business performance was minimal and the Company has maintained a stable supply chain.

Sales	 Slight impact on sales, up 3.1% YoY due to penetration of new drugs Continue activities by utilizing Web interviews and Webinars to prevent infection among healthcare professionals
R&D	 No significant effects have been observed regarding R&D activities at the present time. Enrollment delay has occurred in some clinical trials due to patients refraining from visits to clinics.
Production	 Maintain a stable supply system in production by a strict response We will continue to ensure a stable supply chain with appropriate risk assessment.



Initiatives and Achievements in the First Half of FY2020

Growth of New Products such as RELUMINA[®] and RIFXIMA[®]

Joint Development and Commercialization Agreement for AKP-009 with Kyorin Pharmaceutical


Shares Transfer Agreement with Hataphar

Co-promotion agreement for Riona[®] Tablets with Torii Pharmaceutical

* Promotion of iron deficiency anemia within gynecology and obstetrics (Indication as in the application)



Transformation into New Drug-Based Business





Update of Alliance Activities






Initiatives for Major Themes in FY2020



Contribution to Women's Health Care




Trends in Female Workforce * Previous bulletin





Reasons for Women's Turnover in Employment (2019)

* Previous bulletin




Source: Labour Force Survey 2019, Statistics Bureau, Ministry of Internal Affairs and Communications.

On the other hand, many women have no choice but to leave for health reasons, etc.




Prediction of the Ob/Gyn market



Source: Fuji Economy 2018-2019 Prescription Drug Data Book No. 4 Prohibited from being reproduced without permission



Obstetrics and Gynecology Products by Life Stage







Estimated Number of Cases of RELUMINA's Sales * Drug Price Basis **Uterine Fibroids** *Estimates from Units —Number of Facilities Sales (No. of (Millions of ven) (No. of Facilities) RELUMINA Cases) 700 4,000 **LEUPRORELIN 1.88ma** Sales: ¥650 million Number of Facilities: 3600 3,500 ---- The average cases of LEUPRORELIN 1.88mg Before Release of RELUMINA 600 (January 2018 to February 2019) Copyright © 2020 IQVIA. Release of restrictions on 3,000 Company estimates based on JPM 2018 January to September 2020 40,000 500 the number of days for "Leuprorelin 1.88 Total" is the total value of multiple drugs including in-house products. All rights reserved 35,000 **Prescriptions, March 2020** 2,500 Release of restrictions on the number of days 400 30,000 for prescriptions March 2020 2,000 25,000 300 1,500 20,000 200 1,000 15,000 10,000 100 500 5,000 0 0 0 Oct Dec Jan Feb Oct Sep Nov Чау Aug Чау Jun Jul Aug Mar Jun Jul Sep Mar Apr Apr 2019 2020 2018 2019 2020

After the release of the restriction on the number of days for prescription, increase in sales and number of Prescribers for RELUMINA

Acceleration of switch from LEUPROLELIN 1.88mg after March 2020




RELUMINA RELUMINA

Reasons for selecting RELUMINA (excerpt from physician feedback)

- Oral formulations are preferred over other dosage forms
- Symptoms associated with uterine fibroids can be relieved quickly
- Flare-up phenomena* can be avoided
- Suitable before surgery
- Cases of enlarged myoma
- Patients with uncontrolled bleeding

Approx. **20,000** people take RELUMINA (as of September 2020)

* As female hormone secretion increases transiently during the early phase of administration, symptoms such as abnormal genital bleeding or lower abdominal pain occur




Source: Japan Medical Data Center

We expect further switching from GnRH and other hormonal agents



LEP Preparations (Jemina, FREWELL)





Internal Medicine







Revised version of Clinical Practice Guidelines for Cirrhosis.

Published in November 2020 *First revision after the launch of RIFXIMA

(applicable partial summary)

Because RIFXIMA is an effective treatment for hepatic encephalopathy, as is synthetic disaccharides, It has been recommended as a "basic therapeutic agent".


Strength of recommendation:

Strongly recommended * Top grade

Evidence level:

* Top grade

We will complete providing information to Board Certified Gastroenterologist and to Board Certified Hepatologist ASKA aims to further contribute as the First-line treatment for hepatic encephalopathy





Initiatives in the Thyroid Area

Launched on June 29, 2020

THYRADIN®-S I.V. INJECTION 200µg

[Indications]

- Myxoedema coma
- Hypothyroidism

(Limited to cases in which treatment with oral levothyroxine sodium is not appropriate)

Developed as "Unapproved medicine / Offlabel medicine with high medical needs" by ASKA in response to a request from the MHLW



Trends in the sales of thyroid products

THYRADIN MERCAZOLE PROPACIL

Image: Straight of the straigh

Approved for marketing on August 17, 2020

MELCAZOLE® TABLETS 2.5 mg

* Scheduled for release in February 2021

[Indication]

Hyperthyroidism

Half-dose products that meet the high needs of medical institutions



Research and Development



Development Pipeline

R&D Status (as of November 2020)

Changes from the previous report

Development code (Generic name) Indication	PhI	Phll	Phili	Application	Approval
CDB-2914 (Ulipristal) Uterine fibroids					Filed
TAK-385 (Relugolix) Endometriosis				PhIII Completed	
AKP-501 (Folitropin gamma) Infertility		PhI Completed			
LF111 (Drospirenone) Contraception		PhI/II Started			
L-105 (Rifaximin) Hepatic encephalopathy (Children)			PhII/III Ongoing	9	
L-105 (Rifaximin) Crohn's disease		PhI Completed			

AKP-009	Ph		
Benign Prostatic Hyperplasia	Ongo	ing	



In-house AKP-009 (new androgen-receptor modulators)



Agreement concluded for Joint Development and Commercialization with Kyorin Pharmaceutical

* September 30, 2020 press release

AKP-009 [A Novel prostatic hyperplasia drug from ASKA R&D]

Prospective indication: Urinary dysfunction associated with benign prostatic hyperplasia Domestic development timeline: Phase II trials (scheduled for Q4 2019 to Q4 2020)

\sim Product Feature \sim

Expectations "A high prostate atrophy effect" and "Increase efficacy for voiding function"

The contract agreement with Kyorin Pharmaceutical is for the treatment in urology. It is expected that this will lead to an effective and efficient joint drug development.



Progress in the Development Pipeline

Licensed from Takeda Pharmaceutical RELUMINA Phill completed	 Planned Indication: Improvement of pain for endometriosis Market: Approx. 2.6 million patients (10% of menstrual women) It can be administered orally, and it is expected to improve patient's QOL and symptoms by promptly lowering their sex hormone (estrogen and progesterone) levels
License agreement with Insud Pharma (Spain)	Planned Indication: Contraception Market: Approx. 4.7 million sheets for oral contraceptives per year
LF111 (Drospirenone) PhI/II started	 Under development as the first luteinizing hormone single-agent oral contraceptives in Japan It does not contain estrogen and can be used in women who are at risk for thromboembolism. Exclusive Rights for the Development and Distribution in Japan and sub-licensing in Korea

Expanding the development pipeline by promoting in-house drug discovery and drug introduction activities



Global Expansion



Global Expansion

Concluded a stock transfer agreement with Ha Tay Pharmaceutical Joint Stock Company (Know as Hataphar)

Completed a 24.9% share transfer agreement with Hataphar, the second largest commercial company in the Vietnamese pharmaceutical industry as a strategic partner

Synergies between ASKA Pharmaceutical's development and manufacturing technologies and Hataphar's local sales capabilities will lead to significant growth in the two companies' business operations.



[Overview of Hataphar] Year of founding: 1965 Headquarter location: Hanoi, Vietnam Net sales: ¥9.8 billion (FY2019) Net income: ¥430 million (FY2019) Net assets: ¥1.5 billion (FY2019) Total assets: ¥3.54 billion (FY2019) * 1VND=0.0048JPY



New Medium-Term Management Plan (FY2021-FY2025)

In progress for announcement within FY2020



[Reference] Non-Financial Information (ESG) Topics



SDGs

2030

Initiatives for SDGs



2020

Considering the role that a pharmaceutical company should play in the future, contributing to SDG activities.

Established



Contribution items of ASKA

- 3. Good Health and Well-being
- 5. Gender Equality
- 7. Affordable and Clean Energy
- 12. Responsible Consumption and Production
- **13. Climate Action**
- 17. Partnerships




Social Contribution Activity



知ることは、 自分を守ること。


Through ASKA's long experience and knowledge regarding Female Hormones, the Company has established a new organization of "Health Lab Mint+ for Women's health" to support women who suffer from and experience female specific symptoms, on the occasion of our 100th year anniversary





Health Management Initiative

ASKA has been recognized as one of the "White 500": A Certified Health & Productivity Management Outstanding Organizations Recognition Program, conducted jointly by the Ministry of Economy Trade and Industry and the the Nippon Kenko Kaigi, for two consecutive years.



Our HP: ASKA's Health Management

https://www.aska-pharma.co.jp/csr/sustainability/health.html#anc2 * Japanese only



"女性からだ会議® 大賞2020" Excellence Prize

What is the "女性からだ会議[®] 大賞2020"?

A project sponsored by "Thinkparl" which introduces and awards Companies as well as Organizations which commit to working on women's health, preventive measures and activities to fight cancer.



[女性からだ会議[®]大賞2020 Grand Prize]. POLA CO., LTD.

[女性からだ会議[®] 大賞2020 Special Prize]. Rakuten Medical, Inc.

[女性からだ会議®大賞2020 Excellence Prizes]

ASKA Pharmaceutical Co., Ltd. AVEX MANAGEMENT Inc. Suntory Holdings Limited ALL NIPPON AIRWAYS CO., LTD. Japan Airlines Co., Ltd. Nomura Securities Co., Ltd. FUJITSU LIMITED Yahoo Japan Corporation



Participation in the "3rd Shonan Meeting"

Participating in the "**3rd Shonan Meeting**", focusing on providing solutions for social issues concerning **perinatal depression**

The Shonan Meeting began as a consortium of private-sector companies seeking to create businesses for pre-symptomatic conditions. It is facilitated by Shonan iPark and supported by Kanagawa Prefecture (ME-BYO Industry Research Group), Fujisawa City, and Kamakura City

Duration	October 2020-February 2021
Hosted by	Shonan iPark
Sponsored by	Janssen Pharmaceutical K.K.,
Supported by	Kanagawa Prefecture (ME-BYO Industry Research Group), Fujisawa City, and Kamakura City
Participants (8 companies)	ASKA Pharmaceutcal co., Ltd., Aflac Life Insurance Co., Ltd., MTI Ltd., GUNZE LIMITED, Genequest Inc., Mitsubishi Tanabe Pharma Corporation, IBM Japan, Ltd., HYPER CUBE Ltd.

[About Perinatal Depression]

- Perinatal depression is a condition experienced by patients worldwide, affecting 10 to 15% of women with children
- In Japan, the highest cause of death among perinatal women is suicide from perinatal depression





Co-sponsorship in "女性のための働き方改革!「生理快適プロジェクト」"



A project supported by Multi-companies, <u>"The realization of a society in which</u> <u>women can work comfortably"</u> Sponsored by NIKKEI BP INTELLIGENCE GROUP

> Web article series Webinar for media Webinar for working women

↓ Targets of SDGs committed by "生理快適プロジェクト"↓



Project HP: <u>https://special.nikkeibp.co.jp/atclh/DRS/20/seirikaiteki/</u> Web article : <u>https://doors.nikkei.com/atcl/column/19/092400212/</u> * Japanese only Contribute toward the improvement of people's health and progress in medicine through the development of innovative products

あすか製薬株式会社

ASKA Pharmaceutical Co., Ltd.



Inquiries

Corporate Planning Department

Tel : +81-3-5484-8366

e-mail: kouhou@aska-pharma.co.jp